These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35736410)

  • 1. Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria.
    Davison AS; Norman BP; Sutherland H; Milan AM; Gallagher JA; Jarvis JC; Ranganath LR
    Metabolites; 2022 May; 12(6):. PubMed ID: 35736410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS.
    Davison AS; Norman BP; Ross GA; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
    JIMD Rep; 2019 Jul; 48(1):67-74. PubMed ID: 31392115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging.
    Davison AS; Strittmatter N; Sutherland H; Hughes AT; Hughes J; Bou-Gharios G; Milan AM; Goodwin RJA; Ranganath LR; Gallagher JA
    Metabolomics; 2019 Apr; 15(5):68. PubMed ID: 31037385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria.
    Norman BP; Davison AS; Ross GA; Milan AM; Hughes AT; Sutherland H; Jarvis JC; Roberts NB; Gallagher JA; Ranganath LR
    Clin Chem; 2019 Apr; 65(4):530-539. PubMed ID: 30782595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.
    Davison AS; Harrold JA; Hughes G; Norman BP; Devine J; Usher J; Hughes AT; Khedr M; Gallagher JA; Milan AM; J C G H; Ranganath LR
    Mol Genet Metab; 2018 Sep; 125(1-2):135-143. PubMed ID: 30049652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
    Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
    Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria.
    Norman BP; Davison AS; Hickton B; Ross GA; Milan AM; Hughes AT; Wilson PJM; Sutherland H; Hughes JH; Roberts NB; Bou-Gharios G; Gallagher JA; Ranganath LR
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone.
    Davison AS; Norman BP; Smith EA; Devine J; Usher J; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
    JIMD Rep; 2018; 41():109-117. PubMed ID: 29754208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
    J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
    Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
    Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
    Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitisinone causes acquired tyrosinosis in alkaptonuria.
    Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
    Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression.
    Davison AS; Hughes G; Harrold JA; Clarke P; Griffin R; Ranganath LR
    JIMD Rep; 2022 May; 63(3):221-230. PubMed ID: 35433173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.
    Khedr M; Judd S; Briggs MC; Hughes AT; Milan AM; Stewart RMK; Lock EA; Gallagher JA; Ranganath LR
    JIMD Rep; 2018; 40():31-37. PubMed ID: 28942493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4 Weeks of Treatment.
    Davison AS; Norman B; Milan AM; Hughes AT; Khedr M; Rovensky J; Gallagher JA; Ranganath LR
    JIMD Rep; 2018; 41():1-10. PubMed ID: 29147990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
    Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.